Risperidone combined valproate for the treatment of acute mania clinical efficacy and safety were observed and analyzed. Methods: According to the paral el-group approach in recent years, our hospital admitted 90 cases of acute mania patients were divided into observation group (risperidone combined VPA) with the reference group (risperidone), each of 45 cases, respectively, in before treatment, 7d, 14d, 28d BRMS scores of the two groups were observed, treatment groups were compared and incidence of adverse reactions. Results:Before treatment, the patients showed no statistical y significant BRMS score (P> 0.05), after treatment, the observation group 7d, 14d, 28dBRMS score significantly better than the reference group (P <0.05); observation group was significantly greater than the total efficiency reference group (P <0.05); groups incidence of adverse reactions in patients with no significant difference (P> 0.05). Conclusion: Risperidone treatment of acute mania combined effect of valproate precise, safe, can be widely used.
NETL
NSTL
万方数据
